Did you know?

MORRISTOWN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...NASDAQ:ICPT opened at $19.00 on Wednesday. The company has a quick ratio of 2.52, a current ratio of 4.22 and a debt-to-equity ratio of 3.12. Intercept Pharmaceuticals has a 1-year low of $8.82 and a 1-year high of $21.86. The firm has a market capitalization of $794.77 million, a price-to-earnings ratio of -12.84 and a beta of 0.88.The new research reports from Capital Review, available for free download at the links above, examine American Tower Corporation (REIT) (NYSE:AMT), Lowe's Companies, Inc. (NYSE:LOW), Mimecast ...Contact Data Contact For more information about Intercept Pharmaceuticals, please contact: Mark Vignola +1-646-747-1000 [email protected] Christopher Frates +1-646-757-2371 media ...With a price-to-sales (or "P/S") ratio of 2.3x Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT) may be sending very bullish signals at the moment, given that almost half of all the Biotechs ...22 thg 5, 2023 ... (Nasdaq: ICPT) securities. Click Here To Join Investigation. If you purchased Intercept securities and would like to discuss our ...MORRISTOWN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development...Le cours de l'action INTERCEPT PHARM ICPT sur Boursorama : historique de la cotation sur NASDAQ, graphique, actualités, consensus des analystes et ...Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)'s sale to Alfasigma S.p.A. for $19.00 per share in cash. If you are an Intercept shareholder, click here to learn more about your rights and options.Jul 19, 2022 · Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Liquidia Corp (Symbol: LQDA), where a total of 6,602 contracts have traded so far ... On that note, Intercept Pharmaceuticals (NASDAQ:ICPT) shares crashed in the previous year due to a CRL. In making a successful turnaround, Intercept recently sent its lead drug (obeticholic acid ...INTERCEPT PHARMACEUTICALS INC ( ICPT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the ...Bank of New York Mellon Corp grew its position in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Free Report) by 24.1% during the second quarter, HoldingsChannel reports. The firm owned 218,165 ...BOLOGNA, Italy and MORRISTOWN, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT, “Intercept”), a leading biopharmaceutical company in rare and serious liver diseases, today announced that …Apr 27, 2023 · Intercept recognized $68.0 million in net sales in the first quarter 2023 compared to $59.2 million in net sales in the prior year quarter. In the quarter ended March 31, 2023, Intercept recorded ... By Colin Kellaher. Intercept Pharmaceuticals Inc. on Friday said the U.S. Food and Drug Administration will hold an advisory committee meeting to discuss the biopharmaceutical company's resubmitted application seeking approval of obeticholic acid. The Morristown, N.J., company, which is once again seeking an FDA green light for obeticholic acid ...NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel ...Sep 26, 2023 · Intercept Pharmaceuticals ( NASDAQ: ICPT) is unlikely to see any other bidders after agreeing to a $19 per share sale to Alfasigma, according to analysts. "We also see an extremely low likelihood ... Advisory Committee Meeting scheduled for May 19, 2023. PDUFA Target Action Date is June 22, 2023. MORRISTOWN, N.J., March 10, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ...MORRISTOWN, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Find the latest analyst research for Intercept Pharmaceuticals, Inc. Common Stock (ICPT) at Nasdaq.com. ... Based on analysts offering 12 month price targets for ICPT in the last 3 months.Find the latest stock market trends and activity today. Compare key indexes, including Nasdaq Composite, Nasdaq-100, Dow Jones Industrial & more. There were no results found for ICPT:NSQ among equities. Explore our tools. Growth CalculatorBETA. Explore the time value of money, the impact of regular ...Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination ...

Shares of the non-viral liver disease specialist Intercept Pharmaceuticals ( ICPT) are under heavy pressure today. Specifically, the drugmaker's stock was down by 9.7% on exceptionally high volume ...NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel ...Dec 20, 2021 · Follow. NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ... Nov 27, 2023 · Intercept Pharmaceuticals (NASDAQ:ICPT – Get Free Report) and Opthea (NASDAQ:OPT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Insider & Institutional Ownership 83.8% of ... In October 2012, Intercept Pharmaceuticals (NASDAQ:ICPT) completed its initial public offering ("IPO") of 5m shares priced at $15 per share, raising ~$75m to fund development of a then Phase 3 ...

2023 Financial Guidance. Intercept has updated its full-year 2023 Ocaliva ® net sales guidance to $320-$340 million from $310-$340 million. In June 2023, the Company lowered 2023 non-GAAP ...22 thg 5, 2023 ... (Nasdaq: ICPT) securities. Click Here To Join Investigation. If you purchased Intercept securities and would like to discuss our ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Intercept Pharmaceuticals Inc stock price (. Possible cause: Find the latest historical data for Intercept Pharmaceuticals, Inc. Com.